Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma-Reference-Cited by-同舟云学术

Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma

Published:2019-01-31 Issue:2 Volume:145 Page:531-539
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Tschirdewahn Stephan¹,Panic Andrej¹,Püllen Lukas¹,Harke Nina N.¹,Hadaschik Boris¹,Riesz Peter²,Horváth Andras²,Szalontai Janos²,Nyirády Peter²,Baba Hideo A.³,Reis Henning³^ORCID,Szarvas Tibor¹²^ORCID

Affiliation:

1. Department of Urology, West German Cancer CenterUniversity of Duisburg‐Essen, University Hospital Essen Essen Germany

2. Department of UrologySemmelweis University Budapest Hungary

3. Institute of Pathology, West German Cancer CenterUniversity of Duisburg‐Essen, University Hospital Essen Essen Germany

Funder

National Research, Development and Innovation Office

NVKP

János Bolyai Research Scholarship of the Hungarian Academy of Sciences

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32124

Reference30 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis

3. Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma

4. Oncofetal Protein IMP3, a New Cancer Biomarker

5. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IGF2BP3/NCBP1 complex inhibits renal tubular senescence through regulation of CDK6 mRNA stability;Translational Research;2024-11

2. The role of RNA-modifying proteins in renal cell carcinoma;Cell Death & Disease;2024-03-19

3. circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma;Clinical and Translational Medicine;2023-12

4. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma;Cancer Research;2023-09-27

5. Targeting IGF2BP3 in Cancer;International Journal of Molecular Sciences;2023-05-29